D. Bodkin

发表

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer

C. Redfern, G. Daniels, C. Garrett, 2011, Cancer Chemotherapy and Pharmacology.

Simultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform

D. Hoon, D. Bodkin, A. Kinana, 2020, Frontiers in Bioengineering and Biotechnology.

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.

F. Shepherd, P. Ellis, D. Ellison, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial.

R. Govindan, M. Ranson, N. Rizvi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC)

F. Shepherd, D. Ellison, Martin R. Weber, 2007 .

O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa™) in patients with NSCLC: Results of a randomized, double-blind Phase II study

R. Govindan, M. Ranson, N. Rizvi, 2005 .

IDEC-C 2 B 8 ( Rituximab ) Anti-CD 20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin ’ s Lymphoma

D. Maloney, K. Foon, R. Schilder, 1997 .

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

D. Maloney, K. Foon, R. Schilder, 1997 .

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

D. Maloney, J. Rosenberg, C. White, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

I Royston, D. Maloney, K. Foon, 1997, Blood.

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.

R. Govindan, M. Ranson, N. Rizvi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer

F. Shepherd, P. Ellis, D. Ellison, 2007 .

Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.

T. N. Campbell, W. Huse, J. Gutheil, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer

Hua Liu, Balazs Halmos, Thomas J Lynch, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study.

D. Bodkin, D. Richards, M. Neubauer, 2005, Clinical lung cancer.

Pharmacokinetic analysis of serum concentrations of the chimeric anti-CD20 antibody IDEC-C2B8 in patients with relapsed B cell lymphoma

D. Maloney, J. Rosenberg, C. White, 1995 .

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy

C. Azzoli, K. Kelly, J. R. Pereira, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC)

T. Lynch, B. Halmos, O. Eton, 2007 .

O-140 Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX™) in patients with non-small-cell lung cancer who are ≥ 70 years of age or performance status (PS) = 2

D. Bodkin, M. Neubauer, M. Bolton, 2003 .

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy

C. Azzoli, K. Kelly, J. R. Pereira, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2.

A. Dowlati, R. Lilenbaum, D. Bodkin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.